Navigation Links
Meningitis vaccine study gets £200,000 boost
Date:2/7/2008

meningococci.

Meningitis UK launched its Search 4 a Vaccine Campaign in 2007 to help raise 7million over the next seven years to fund vital work into developing a vaccine against Group B. This innovative project is just one of the studies the charity is funding.

Meningitis UKs Chief Executive Steve Dayman said: We are extremely pleased to be funding Dr Karl Wooldridge and his team in their work to discover more about the proteins secreted by the Meningitis B bacteria. If this research can go forward to help develop a vaccine, thousands of lives could be saved.

Meningitis can be incredibly hard to detect as many of its symptoms are often similar to more minor ailments such as the common cold or flu, plus there are occasions when people show no, or very few, symptoms. For these reasons, we believe the only way to eradicate meningitis completely is through the development of a preventative vaccine.


'/>"/>

Contact: Karl Wooldridge
karl.wooldridge@nottingham.ac.uk
University of Nottingham
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Schedules Revised for Flu, Meningitis Vaccines
2. New Meningitis Vaccine Works in Infants
3. Steroid Fails to Ease Meningitis in Trials
4. Meningitis Shot Available, Effective Year-Round
5. Tattooing Best Way to Deliver DNA Vaccines
6. Novel molecules developed at UB can boost vaccine potency
7. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
8. Another Study Finds No Link Between MMR Vaccine and Autism
9. New hospital standards needed for pediatric flu vaccines
10. Experimental Vaccine Halts Prostate Cancer in Mice
11. Novel vaccine concept developed by scientists at the Wistar Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...ough the number of jobs created in the medical fie...ed a different kind of slowdown: they laid off few... Seattle, WA (PRWEB) July 25, 2...dical field slowed in June overall, pharmaceutical...hat will be music to the ears of sales representat...
(Date:7/25/2008)...f Marketing Exclusivity Begins -, CORONA, Calif.,...uticals, Inc. (NYSE: WPI ), a leading specialty p...bsidiary has commenced commercial,shipment of its ... the 40mg,strength from its Davie, Florida manufac...atson has 180 days of marketing exclusivity for be...
(Date:7/25/2008)...5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc.,a ...oday announced that it,has launched amiodarone HCl...ted for the treatment and prophylaxis of frequentl...ically unstable ventricular,tachycardia -- a poten...nt,s amiodarone HCl injection will be available im...
(Date:7/25/2008)...5 /PRNewswire/ -- AutoGenomics, Inc. today,announc...orm S-1 with the,Securities and Exchange Commissio... of shares of its common stock. The number of shar... expected to be offered by,AutoGenomics, Inc., and...en,determined., J.P. Morgan Securities Inc. is ac...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...ron overdose during pregnancy could be harmful, ac...ften given to combat anemia in pregnancy but many...e the blood is unable to carry enough oxygen due t...ecause each red blood cell is unable to carry norm...
...he California Alliance for Inclusive Communities (...ed suicide and Assembly Bill 374. They join the ma...anizations already opposing assisted suicide. CAI... behalf of groups with developmental and other dis...
... new report released today by the Pharmaceutical R... that biopharmaceutical researchers are testing 27... death of Americans -- heart disease and stroke. ...cal trials or under review by the Food and Drug Ad...
...ith the advent of a possible new blockbuster drug ... of nicotine, alcohol, and drug addictions, global...nts are expected to rise from revenues of little o...on in 2010, according to Smoking Cessation and Add...
Other Medicine News:Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2
(Date:7/23/2008)...uly 23 /- FluoroPharma Inc., a compan... for the Positron Emission Tomography,(PET) market...s novel,Fluorine-18 labeled tracer for myocardial ...cardiovascular product to complete Phase I clinica...igned to assess the blood flow in the,heart (myoca...
(Date:7/23/2008)...July 23 /- Dendreon Corpora...cts the Independent Data,Monitoring Committee (IDM...of overall survival relating to the Company,s Phas...oma Treatment, also known as D9902B) clinical tria...ompany,s investigational,active cellular immunothe...
(Date:7/22/2008)...efficacy results from a multi-center 293-patient E...ronto Stock Exchange Symbol: CYT, MONTREAL, July ...es,Inc., the global leader in cryotherapy products...t results previously presented from three,European...rctic Front(R),were published earlier today in th...
(Date:7/22/2008)...eting to Discuss Development Plan Completed Succes...tCall/ -- Amarin Corporation,plc (NASDAQ: AMRN ) ...,officials at the U.S. Food and Drug Administratio...AMR101 for the treatment of,hypertriglyceridemia. ...ding to Phase 3 with AMR101 in hypertriglyceridemi...
Breaking Medicine Technology:FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Polished to perfection 23702 1Polished to perfection 23702 2Zooming in on genetic shuffling 3984 1Zooming in on genetic shuffling 3984 2RNA emerges from DNAs shadow 3982 1RNA emerges from DNAs shadow 3982 2RNA emerges from DNAs shadow 3982 3James Briscoe awarded 2008 EMBO Gold Medal 3980 1James Briscoe awarded 2008 EMBO Gold Medal 3980 2James Briscoe awarded 2008 EMBO Gold Medal 3980 3
...nce of Recurrent Wheeze by,Almost Half, ABBOTT PAR...wswire-FirstCall/ -- Abbott and MedImmune today an...uly issue of Journal of,Pediatrics, showing that t...recurrent wheezing in premature infants by almost,...ure infants without,chronic lung disease who recei...
...Myeloma Workshop held in,Kos, Greece demonstrates ...h bortezomib, dexamethasone and lenalidomide plus,...y multiple,myeloma, and as a single agent in patie...obulinemia, NEW YORK, June 29, 2007 /PRNewswire-Fi...nnounced that 4 posters were,presented at the 11th...
Other Medicine Technology:New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7
...te Focus from Thermo Labsystems was designed speci...performance. Advanced features such as the new fa...n microvolumes help to define this as a new leader...le handle plate offers a custom fit for different ...
...igital offers improved ergonomics for today's exac...fied grippy finger rest and the large display wind...ipette Digitals also feature soft-touch tip ejecti....) and super blow-out for 0.2 - 50ul micro volume ...
...els cover the range from 2ul to 5000ul. Fills and...prevents inadvertent volume change. Novel hand gr...te is autoclavable at 121C(250F). To prevent corr...ble for one-handed operation. Auto or Normal trig...
...pettor is the #1 Pipettor for sub-microliter pipet...iability. Continuously adjustable. Features lPLUS,...ter. Easy interchangeable ejector buttons to fit l...ip ejector with three different lengths. Air-displ...
Medicine Products: